Organogenesis projects 25%-38% revenue decline in 2026 amid CMS-driven market disruption
Source: SeekingAlpha
2026-02-26 23:58:32 ET
More on Organogenesis Holdings
- Organogenesis Holdings Inc. (ORGO) Q4 2025 Earnings Call Transcript
- Organogenesis: High-Tech Skin Substitute Company On Sale
- Organogenesis Holdings GAAP EPS of $0.24 beats by $0.03, revenue of $225.1M beats by $52.42M
- Organogenesis drops as Medicare to pull skin substitute LCDs (update)
- Seeking Alpha’s Quant Rating on Organogenesis Holdings
Read the full article on Seeking Alpha
For further details see:
Organogenesis projects 25%-38% revenue decline in 2026 amid CMS-driven market disruption
Organogenesis Holdings Inc.
NASDAQ: ORGO
ORGO Trading
-2.83% G/L:
$2.655 Last:
282,101 Volume:
$2.71 Open:
ORGO Latest News
February 26, 2026 04:05:00 pm
Organogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Results, Posts Record Revenue
February 19, 2026 04:05:00 pm
Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026
ORGO Stock Data
$490,515,429
46,830,580
2.02%
145
N/A
Pharmaceuticals
Healthcare
US
Canton
